After the observation of encouraging activity with pertuzumab and trastuzumab combination therapy in patients with HER2-positive MBC who had experienced progression on trastuzumab-based therapy, 18 ...

Pertuzumab and pertuzumab/trastuzumab in breast cancer: now minor added benefit Advantages in overall survival and recurrence often only become apparent after a longer period of time – current ...

PURPOSEWe aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (EBC) treatment by replacing taxanes and trastuzuma ...

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy ...

The DESTINY-Breast09 trial randomized 1157 patients with locally advanced or metastatic HER2-positive breast cancer to receive either trastuzumab deruxtecan plus pertuzumab (n = 383), trastuzumab ...

Trastuzumab and pertuzumab are 2 cancer drugs given together. It’s used to treat early, locally advanced and secondary breast cancer that is HER2 positive. You pronounce trastuzumab as ...

Participants in the pertuzumab arm received: Docetaxel 75-100 mg/m 2 every three weeks for six cycles or until progression; Herceptin 8 mg/kg loading dose followed by 6 mg/kg every three weeks ...

In addition, CLEOPATRA, a Phase III study evaluating the efficacy and safety profile of pertuzumab and Herceptin plus chemotherapy as a first-line regimen in people with HER2-positive metastatic ...

Patients with HER2-positive breast cancer, whose disease has progressed after being treated initially with pertuzumab in combination with trastuzumab and a taxane, can respond well to treatment ...

Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA) for pertuzumab and granted Priority Review for use in combination with Herceptin (trastuzumab ...

Despite significant progress, HER2-positive mBC remains an incurable disease. “These results with pertuzumab combined with Herceptin and docetaxel are very encouraging and represent our ...

-- Phase II Study Evaluating a Novel Targeted Combination Regimen Showed Promising Results in the Neoadjuvant (Pre-surgery) Setting -- SAN ANTONIO, Texas--(BUSINESS WIRE)-- Genentech, a member of the ...